Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 31,000 shares, a decline of 11.9% from the July 15th total of 35,200 shares. Based on an average daily trading volume, of 9,800 shares, the short-interest ratio is presently 3.2 days.
Intellipharmaceutics International Price Performance
OTCMKTS IPCIF traded down $0.02 on Monday, hitting $0.09. 1,000 shares of the company were exchanged, compared to its average volume of 10,463. The firm has a market capitalization of $2.81 million, a P/E ratio of -0.31 and a beta of 1.67. The company's 50 day moving average price is $0.10 and its 200-day moving average price is $0.12. Intellipharmaceutics International has a twelve month low of $0.08 and a twelve month high of $0.30.
Get Intellipharmaceutics International alerts:Intellipharmaceutics International (OTCMKTS:IPCIF – Get Rating) (TSE:I) last released its quarterly earnings results on Thursday, July 21st. The company reported ($0.05) EPS for the quarter.
Intellipharmaceutics International Company Profile
(Get Rating)
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Read More
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.